Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated